Postherpetic Neuralgia
📧 Sign up to get email alerts when something new happens for Postherpetic Neuralgia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-10-15FDA Approved: GABAPENTIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for gabapentin filed by Aurobindo Pharma Limited. This action approves a generic formulation of …
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
The study investigates whether obesity and related factors influence the risk of herpes zoster and postherpetic neuralgia. It is currently a…
-
FDA approval · 2024-09-09FDA Approved: GABAPENTIN — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for gabapentin from Rising Pharma Holdings, Inc. The approval indicates a modification to the dr…
-
FDA approval · 2024-08-23FDA Approved: PREGABALIN — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for pregabalin from Solco Healthcare US, LLC, granting approval for changes related to the generic p…
-
FDA approval · 2024-07-31FDA Approved: QUTENZA — Supplemental Application (Averitas Pharma Inc)
The FDA approved a supplemental application for QUTENZA (capsaicin patch) from Averitas Pharma Inc. The approval covers changes described in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-07-12FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: The Success of Lumbar Sympathetic Ganglion Block Using Lower Extremity Perfusion Index [NA]
A completed clinical trial evaluated the effectiveness of a lumbar sympathetic ganglion block using a lower extremity perfusion index for ch…
-
CLINICAL_TRIALS trial_result · 2024-06-24Clinical Trial Update: A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. [Phase 1]
Phase 1 trial update for iN1011-N17 assessing safety, tolerability, and PK/PD in healthy volunteers and postherpetic neuralgia patients; rec…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers [Phase 1]
A Phase 1 single ascending dose study assessed the safety, tolerability and PK/PD of iN1011-N17 in healthy volunteers and has completed.
-
FDA approval · 2024-06-05FDA Approved: PREGABALIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approves the supplemental ANDA for pregabalin from Aurobindo Pharma Limited, enabling the marketing of a generic pregabalin product in t…
-
FDA approval · 2024-05-29FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Gabapentin submitted by Amneal Pharmaceuticals LLC under ANDA202024.
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Sympathetic Ganglion Block [NA]
This clinical trial compares sympathetic blockade using stellate ganglion block versus thoracic sympathetic ganglion block for chronic neuro…
-
CLINICAL_TRIALS research · 2024-05-13Clinical Trial Update: Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.
This clinical trial update describes a study to develop predictive models for treating recurrent herpes zoster neuralgia after spinal cord e…
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN). [Phase 2]
Phase 2 randomized trial evaluating SPM 927 for postherpetic neuralgia has completed.
-
FDA approval · 2024-04-08FDA Approved: GABAPENTIN — Original Application (Laurus Labs Limited)
FDA approved Laurus Labs Limited's Original Application for gabapentin, permitting the marketing of a generic gabapentin product.
-
FDA approval · 2024-02-26FDA Approved: GABAPENTIN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approval of Gabapentin in an original application for Camber Pharmaceuticals, establishing a generic version of Gabapentin.
-
FDA approval · 2024-02-26FDA Approved: GABAPENTIN — Original Application (Epic Pharma, LLC)
FDA approved the original application for gabapentin from Epic Pharma, LLC, introducing a generic gabapentin product to the market.
-
FDA approval · 2024-02-20FDA Approved: GABAPENTIN — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for gabapentin from Rising Pharma Holdings, Inc., authorizing changes to the approved generic produc…
-
FDA approval · 2024-01-24FDA Approved: GABAPENTIN — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the Gabapentin original ANDA from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2024-01-24FDA Approved: PREGABALIN — Supplemental Application (MARKSANS PHARMA LIMITED)
FDA approved a supplemental application for pregabalin submitted by Marksans Pharma Limited (ANDA 216197).
-
FDA approval · 2024-01-17FDA Approved: GABAPENTIN — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for gabapentin, a generic version of the anticonvulsant used for partial seizures …
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN) [Phase 2]
Phase 2 trial update evaluating SR419 for efficacy and safety in postherpetic neuralgia has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions [Phase 4]
Phase 4 trial evaluating lidocaine patch 5% alone, gabapentin alone, and combination for relief of peripheral neuropathic pain.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain [Phase 4]
Phase 4 trial evaluating Lidoderm as add-on therapy for postherpetic neuralgia, diabetic neuropathy, or low back pain; study completed.
-
FDA approval · 2023-12-13FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for LYRICA (pregabalin) from Pfizer's Parke-Davis division.